Chugai Pharmaceutical Co. Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL… Read more
Chugai Pharmaceutical Co. Ltd (CHGCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.064x
Based on the latest financial reports, Chugai Pharmaceutical Co. Ltd (CHGCF) has a cash flow conversion efficiency ratio of 0.064x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($130.16 Billion) by net assets ($2.03 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chugai Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Chugai Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chugai Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chugai Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HUATEI SECS.CO GDR S/10
F:206G
|
N/A |
|
FirstEnergy Corporation
NYSE:FE
|
0.060x |
|
Tata Consultancy Services Limited
NSE:TCS
|
0.121x |
|
Halliburton Company
NYSE:HAL
|
0.111x |
|
Workday Inc
NASDAQ:WDAY
|
0.066x |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
0.080x |
|
Sampo OYJ
PINK:SAXPY
|
0.003x |
|
Verisk Analytics Inc
NASDAQ:VRSK
|
1.108x |
Annual Cash Flow Conversion Efficiency for Chugai Pharmaceutical Co. Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Chugai Pharmaceutical Co. Ltd from 2003 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.03 Trillion | $389.79 Billion | 0.192x | -18.33% |
| 2024-12-31 | $1.90 Trillion | $447.60 Billion | 0.235x | -6.65% |
| 2023-12-31 | $1.63 Trillion | $409.93 Billion | 0.252x | +47.14% |
| 2022-12-31 | $1.42 Trillion | $244.11 Billion | 0.171x | -27.19% |
| 2021-12-31 | $1.19 Trillion | $279.63 Billion | 0.235x | +12.50% |
| 2020-12-31 | $980.00 Billion | $205.03 Billion | 0.209x | -13.54% |
| 2019-12-31 | $853.99 Billion | $206.64 Billion | 0.242x | +53.74% |
| 2018-12-31 | $756.53 Billion | $119.07 Billion | 0.157x | +1.33% |
| 2017-12-31 | $692.90 Billion | $107.62 Billion | 0.155x | +158.89% |
| 2016-12-31 | $646.50 Billion | $38.79 Billion | 0.060x | -40.19% |
| 2015-12-31 | $627.27 Billion | $62.92 Billion | 0.100x | +61.90% |
| 2014-12-31 | $597.76 Billion | $37.03 Billion | 0.062x | -33.65% |
| 2013-12-31 | $573.20 Billion | $53.52 Billion | 0.093x | -40.80% |
| 2012-12-31 | $490.07 Billion | $77.30 Billion | 0.158x | +4.05% |
| 2011-12-31 | $459.07 Billion | $69.59 Billion | 0.152x | +337.49% |
| 2010-12-31 | $449.39 Billion | $15.57 Billion | 0.035x | -77.34% |
| 2009-12-31 | $434.69 Billion | $66.46 Billion | 0.153x | +54.57% |
| 2008-12-31 | $397.07 Billion | $39.28 Billion | 0.099x | -36.78% |
| 2007-12-31 | $385.80 Billion | $60.36 Billion | 0.156x | +51.15% |
| 2006-12-31 | $391.60 Billion | $40.54 Billion | 0.104x | -40.77% |
| 2005-12-31 | $370.00 Billion | $64.66 Billion | 0.175x | +9.39% |
| 2004-12-31 | $322.31 Billion | $51.49 Billion | 0.160x | +229.23% |
| 2003-12-31 | $297.62 Billion | $-36.80 Billion | -0.124x | -- |